TDC
CARM

Thompson Davis & Co’s Carisma Therapeutics CARM Stock Holding History

Thompson Davis & Co’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-200
Closed -$1K – 1070
2016
Q1 		$1K Sell
200
-100
-33% -$1.38K ﹤0.01% 997
2015
Q4 		$18K Buy
+300
New +$17K 0.03% 497

Other funds holding CARM

FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Thompson Davis & Co's CARM Position: Q2 2016 in Review

Thompson Davis & Co sold out of Carisma Therapeutics (CARM) in Q2 2016, closing a stake of 200 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in CARM in Q4 2015 and held it in 2 quarters. The position peaked at $18K in Q4 2015. 25 funds tracked by Wall St. Rank hold CARM as of Q2 2016.

  • Thompson Davis & Co reported no remaining Carisma Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 200 Carisma Therapeutics shares in Q2 2016, an estimated $1K.
  • Thompson Davis & Co first reported a position in Carisma Therapeutics in Q4 2015 and held it in 2 quarters.
  • Thompson Davis & Co's Carisma Therapeutics position peaked at $18K in Q4 2015.
  • 25 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2016.

Based on Thompson Davis & Co's 13F filing for Q2 2016, filed 9 Aug 2016.